Drug Profile
Sunobinop - Imbrium Therapeutics/Shionogi
Alternative Names: IMB-115; IMB-115 tosylate; IT-1315; RSC117957; S-117957; Sunobinop tosylate; V-117957Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Purdue Pharma; Shionogi
- Developer Imbrium Therapeutics; Purdue Pharma; Shionogi
- Class Analgesics; Aza compounds; Carboxylic acids; Quinoxalines; Sleep disorder therapies; Small molecules
- Mechanism of Action Nociceptin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Insomnia; Interstitial cystitis
- Phase I Overactive bladder
- Preclinical Fibromyalgia
- Discontinued Dental pain; Neuropathic pain